<!DOCTYPE html>
<html>
<head>
<title>Skilarence, INN-dimethyl fumarate</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:274pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ANNEX I</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 30 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 120 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 30 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each gastro-resistant tablet contains 30 mg dimethyl fumarate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Excipient with known effect </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each gastro-resistant tablet contains 34.2 mg lactose (as monohydrate). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 120 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each gastro-resistant tablet contains 120 mg dimethyl fumarate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Excipient with known effect </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each gastro-resistant tablet contains 136.8 mg lactose (as monohydrate). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastro-resistant tablet </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 30 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">White, film-coated, round, biconvex tablet with a diameter of approximately 6.8 mm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 120 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blue, film-coated, round, biconvex tablet with a diameter of approximately 11.6 mm. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">systemic medicinal therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence is intended for use under the guidance and supervision of a physician experienced in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diagnosis and treatment of psoriasis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">To improve tolerability of Skilarence, it is recommended to begin treatment with a low initial dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with subsequent gradual increases. In the first week, a 30 mg dose is taken once daily (1 tablet in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evening). In the second week, a 30 mg dose is taken twice daily (1 tablet in the morning and 1 in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">evening). In the third week, a 30 mg dose is taken three times daily (1 tablet in the morning, 1 at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">midday, and 1 in the evening). From the fourth week, treatment is switched to only 1 tablet of </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a 120 mg dose in the evening. This dose is then increased by one 120 mg tablet per week at different </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">times of day for the subsequent 5 weeks, as shown in the table below.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The maximum daily dose allowed is 720 mg (six 120 mg tablets). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:216pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Number of tablets </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:417pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Total daily dose (mg) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:141pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Morning </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:240pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Midday </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:336pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Evening </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:417pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">of dimethyl fumarate  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:194pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Skilarence 30 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:466pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">60 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:461pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">90 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:191pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Skilarence 120 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:466pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">120 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">240 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">360 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">480 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">600 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">9+ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:159pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:256pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:353pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:458pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">720 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If a particular dose increase is not tolerated, it may be temporarily reduced to the last tolerated dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If treatment success is observed before the maximum dose is reached, no further increase of dose is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">necessary. After clinically relevant improvement of the skin lesions has been achieved, consideration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should be given to gradual reduction of the daily dose of Skilarence to the maintenance dose required </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">by the individual. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dose modifications may also be necessary if abnormalities in laboratory parameters are observed (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Elderly patients </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical studies of Skilarence did not include sufficient numbers of patients aged 65 years and above </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to determine whether they respond differently compared to patients under 65 years (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on the pharmacology of dimethyl fumarate, a need for dose adjustment in the elderly is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is needed in patients with mild to moderate renal impairment (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence has not been studied in patients with severe renal impairment, and use of Skilarence is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraindicated in these patients (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dose adjustment is needed in patients with mild to moderate hepatic impairment (see section 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence has not been studied in patients with severe hepatic impairment, and use of Skilarence is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraindicated in these patients (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Skilarence in children below the age of 18 years have not been established. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no data available with Skilarence in paediatric population. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:724pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:736pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For oral use. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablets must be swallowed whole with fluid during or immediately after a meal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:761pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The coating of the gastro-resistant tablets is designed to prevent gastric irritation. Therefore, the tablets </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should not be crushed, divided, dissolved or chewed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:Calibri,sans-serif;font-size:11.04pt">&#x2012;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:Calibri,sans-serif;font-size:11.04pt">&#x2012;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Severe gastrointestinal disorders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:Calibri,sans-serif;font-size:11.04pt">&#x2012;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Severe hepatic or renal impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:Calibri,sans-serif;font-size:11.04pt">&#x2012;</span><span style="font-family:ArialMT,sans-serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:99pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy and breast-feeding. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Haematology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence may decrease leukocyte and lymphocyte counts (see section 4.8). It has not been studied in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with pre-existing low leukocyte or lymphocyte counts. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Before treatment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Prior to initiating treatment, a current complete blood count (including differential blood count and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">platelet count) should be available. Treatment should not be initiated if leukopenia below 3.0x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphopenia below 1.0x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L or other pathological results are identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">During treatment </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">During treatment, a complete blood count with differential should be performed every 3 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Action is needed in the following circumstances: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Leukopenia</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If a marked decrease in the total number of white blood cells is found, the situation should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monitored carefully and treatment should be discontinued at levels below 3.0x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Lymphopenia</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If the lymphocyte count falls below 1.0x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">but is &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 0.7 x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L, blood monitoring should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">performed monthly until levels return to 1.0x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L or higher for two consecutive blood tests at which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">point monitoring can again be performed every 3 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">If the lymphocyte count falls below 0.7x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L, the blood test must be repeated and if the levels are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">confirmed to be below 0.7x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L, then treatment must be stopped immediately. Patients developing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphopenia should be monitored after stopping treatment until their lymphocyte count has returned </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to the normal range (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Other haematological disorders </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therapy should be discontinued and caution is advised if other pathological results occur. In any case, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood counts should be monitored until values have returned to the normal range. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence is an immunomodulator and may affect the way the immune system responds to infection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For patients with pre-existing infections of clinical relevance, the physician should decide if treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">should only be initiated once the infection has resolved. If a patient develops an infection during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment, suspension of treatment should be considered and the benefits and risks should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reassessed prior to re-initiation of therapy. Patients receiving this medicinal product should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">instructed to report symptoms of infection to a physician. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Opportunistic infections/progressive multifocal leukoencephalopathy (PML) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cases of opportunistic infections, particularly of progressive multifocal leukoencephalopathy (PML) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been reported with other dimethyl fumarate-containing products (see section 4.8). PML is an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">opportunistic infection caused by the John-Cunningham virus (JCV) that can be fatal or cause severe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disabilities. PML is probably caused by a combination of factors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A previous infection with JCV is considered a prerequisite for the development of PML. Risk factors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">can include previous immunosuppressive treatment and the existence of certain concomitant disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(such as some autoimmune disorders or malignant haematological conditions). A modified or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">weakened immune system as well as genetic or environmental factors can also constitute risk factors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Persistent moderate or severe lymphopenia during treatment with dimethyl fumarate is also considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">a risk factor for PML. Patients who develop lymphopenia should be monitored for signs and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">symptoms of opportunistic infections, particularly for symptoms indicative of PML. Typical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">symptoms associated with PML are diverse, become worse over days to weeks and include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changes in thinking, memory and orientation leading to confusion and personality changes. If PML is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">suspected, treatment should be stopped immediately and further appropriate neurological and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">radiological examinations performed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Prior and concomitant treatment with immunosuppressive or immunomodulating therapies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Limited data are available on the efficacy and safety of Skilarence in patients who have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">previously treated with other immunosuppressive or immunomodulating therapies. When switching </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients from such therapies to Skilarence, the half-life and mode of action of the other therapy should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be considered in order to avoid additive effects on the immune system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No data are available on the efficacy and safety of Skilarence when taken concomitantly with other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunosuppressive or immunomodulating therapies (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pre-existing gastrointestinal disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence has not been studied in patients with pre-existing gastrointestinal disease. It is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraindicated in patients with severe gastrointestinal disease (see sections 4.3). Gastrointestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tolerability can be improved by following the dose titration schedule on initiating treatment and by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">taking the gastro-resistant tablet(s) with food (see sections 4.2 and 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">During the Phase III placebo-controlled clinical study, renal function was not seen to deteriorate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during therapy across treatment groups. However, Skilarence has not been studied in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">severe renal impairment, and some cases of renal toxicity have been reported during post-marketing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">surveillance with fumaric acid esters. Hence, Skilarence is contraindicated in patients with severe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal impairment (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal function (e.g. creatinine, blood urea nitrogen and urinalysis) should be checked prior to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">initiation of treatment and every 3 months thereafter. In the event of a clinically relevant change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal function, particularly in the absence of alternative explanations, consideration should be given to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose reduction or treatment discontinuation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fanconi syndrome </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Early diagnosis of Fanconi syndrome and discontinuation of Skilarence treatment are important to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">prevent the onset of renal impairment and osteomalacia, as the syndrome is usually reversible. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">most important signs are: proteinuria, glucosuria (with normal blood sugar levels), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperaminoaciduria and phosphaturia (possibly concurrent with hypophosphatemia) (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Progression might involve symptoms such as polyuria, polydipsia and proximal muscle weakness. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rare cases hypophosphataemic osteomalacia with non-localised bone pain, elevated alkaline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phosphatase in serum and stress fractures may occur. Importantly, Fanconi syndrome can occur </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">without elevated creatinine levels or low glomerular filtration rate. In case of unclear symptoms, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fanconi syndrome should be considered and appropriate examinations should be performed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence has not been studied in patients with severe hepatic impairment and is contraindicated in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">these patients (see section 4.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is recommended to monitor hepatic function (SGOT, SGPT, gamma-GT, AP) prior to initiation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment and every 3 months thereafter, since elevation of hepatic enzymes has been observed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">some patients in the Phase III study (see section 4.8). In the event of a clinically relevant change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatic parameters, particularly in the absence of alternative explanations, consideration should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">given to dose reduction or treatment discontinuation (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flushing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients should be made aware that they are likely to experience flushing in the first few weeks of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Lactose </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicinal product contains lactose. Patients with rare hereditary problems of galactose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Sodium </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2018;sodium free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No interaction studies have been performed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence should be used cautiously in combination with other systemic antipsoriatic therapy (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">methotrexate, retinoids, psoralens, ciclosporin, immunosuppressants or cytostatics) (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">During treatment, simultaneous use of other fumaric acid derivatives (topical or systemic) should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">avoided. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Concurrent therapy with nephrotoxic substances (e.g. methotrexate, ciclosporin, aminoglycosides, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, non-steroidal anti-inflammatory drugs (NSAIDs) or lithium) may increase the potential for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal adverse reactions (e.g. proteinuria) in patients taking Skilarence. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In cases of severe or prolonged diarrhoea during treatment with Skilarence, absorption of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products may be affected. Caution should be exercised when prescribing medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with a narrow therapeutic index that require absorption in the intestinal tract. The efficacy of oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraceptives may be reduced and the use of an alternative barrier contraceptive method is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended to prevent possible failure of contraception (see the prescribing information of the oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraceptive). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Consumption of large quantities of strong alcoholic drinks (more than 30% alcohol by volume) should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be avoided because it may lead to increased dissolution rates of Skilarence and, therefore, may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increase the frequency of gastrointestinal adverse reactions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vaccination during treatment with Skilarence has not been studied. Immunosuppression is a risk factor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">for the use of live vaccines. The risk of vaccination should be weighed against the benefit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no evidence for interaction with cytochrome P450 and the most common efflux and uptake </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transporters, thus no interactions are expected with medicinal products metabolised or transported by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">these systems (see section 5.2). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Women of child-bearing potential </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence is not recommended in women of child-bearing potential not using appropriate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">contraception. Additional contraceptive methods in case of stomach and intestinal problems that could </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduce the effectiveness of oral contraceptives could be necessary (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are limited data from the use of dimethyl fumarate in pregnant women. Animal studies have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">shown reproductive toxicity (see section 5.3). Skilarence is contraindicated during pregnancy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether dimethyl fumarate or its metabolites are excreted in human milk. A risk to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">newborns or infants cannot be excluded. Therefore, Skilarence is contraindicated during breast-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">feeding (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There are no human or animal data on the effects of Skilarence on fertility. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence may have a minor influence on the ability to drive and use machines. Dizziness and fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may occur following administration of Skilarence (see section 4.8). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Summary of the safety profile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The most common adverse reactions observed with Skilarence are gastrointestinal events followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">flushing and lymphopenia. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tabulated list of adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following is a list of adverse reactions experienced by patients treated with Skilarence during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical development, post-marketing experience and with Fumaderm, a related medicinal product </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">containing dimethyl fumarate along with other fumaric acid esters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The frequency of adverse reactions is defined using the following conventio</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">n: very common (&#x2265;1/10); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">common (&#x2265;1/100 to &lt;1/10); uncommon (&#x2265;1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">,000 to &lt;1/100); rare (&#x2265;1/10,000</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to &lt;1/1,000); ve</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ry rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&lt;1/</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">10,000)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and not known (cannot be estimated from available data). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">System organ class </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:226pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adverse reactions </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:444pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Frequency </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infections and infestations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Herpes zoster </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known** </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blood and lymphatic system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lymphopenia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Leukopenia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Eosinophilia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Leukocytosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Acute lymphatic leukaemia* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irreversible pancytopenia*</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:723pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:735pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:748pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and nutrition </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Decreased appetite </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:764pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">System organ class </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:226pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Adverse reactions </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:444pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Frequency </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:74pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Headache</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paraesthesia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dizziness* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Progressive multifocal leukoencephalopathy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vascular disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flushing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diarrhoea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Abdominal distension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Abdominal pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nausea </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vomiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dyspepsia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Constipation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Abdominal discomfort </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Flatulence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and subcutaneous tissue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Erythema </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin burning sensation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pruritus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Allergic skin reaction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Proteinuria </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal failure </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fanconi syndrome*</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt"> </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration site conditions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Feeling hot </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Asthenia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Investigations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic enzymes increased </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:226pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Serum creatinine increased </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:444pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">*Additional adverse reactions reported with Fumaderm, a related medicinal product containing dimethyl fumarate along with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">other fumaric acid esters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">**Adverse reactions reported during post marketing experience. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Description of selected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Gastrointestinal disturbances </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data from the Phase III clinical study as well as from the literature show that gastrointestinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with dimethyl fumarate-containing products are most likely to occur during the first 2 to 3 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">after starting treatment. No apparent dose relationship and no risk factors for the occurrence of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions could be identified. Diarrhoea was a common adverse reaction (36.9%) among </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients taking Skilarence, leading to medicinal product withdrawal in about 10% of patients. More </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">than 90% of these diarrhoea events were of mild to moderate severity (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The only adverse reactions that led to discontinuation of treatment in &gt;5% of patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">gastrointestinal reactions. For monitoring recommendations and clinical management of adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions, see section 4.4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Flushing </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on observations in the Phase III clinical study as well as on literature data, flushing is most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">likely to occur during the early weeks of treatment and tends to lessen with time. In the clinical study a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">total of 20.8% of patients receiving Skilarence experienced flushing, which was mild in the majority </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of cases (see section 4.4). Published clinical experience with dimethyl fumarate-containing products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">shows that individual episodes of flushing usually begin shortly after taking the tablets and resolve </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:728pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">within a few hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:753pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Haematological changes </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:766pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Data from the Phase III clinical study as well as from the literature show that changes in </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">haematological parameters are most likely to occur during the first 3 months after starting treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with dimethyl fumarate. In particular, in the clinical study there was a slight decrease in mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lymphocyte counts starting between weeks 3 and 5 and reaching a maximum in week 12 where </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately one third of patients had lymphocyte values below 1.0x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L. The mean and median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">values of lymphocytes remained within the normal range during the clinical study. At week 16 (end of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment), there was no further decline in lymphocyte counts. At week 16 of treatment, 13/175 (7.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of patients wer</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">e noted to have lymphocyte levels &lt;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 0.7x 10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L. Blood sampling for safety clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">laboratory tests at follow-up visits was only performed in case of abnormalities at the preceeding visit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">During the treatment free follow up, lymphocyte levels of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 0.7x 10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L were observed in 1/29 (3.5%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patient at 6 months and 0/28 (0%) at 12 months after stopping treatment. At 12 months after stopping </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment 3/28 (10.7%) of patients had lymphocyte values below 1.0x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L, which would represent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3/279 (1.1%) of the patients started on Skilarence. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the total leukocyte count, a decline became apparent at week </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">12 of treatment;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> it slowly increased </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">again at week 16 (end of treatment)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and 12 months after stopping treatment all patients had values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">above 3.0x10</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">9</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/L. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A transient increase in mean values of eosinophils was noted as early as week 3, reached a maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">at week 5 and 8, and had returned to baseline values at week 16.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For monitoring recommendations and clinical management of haematological adverse reactions, see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">Appendix V</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Symptomatic treatment is indicated in the case of an overdose. No specific antidote is known. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, other immunosuppressants, ATC code: L04AX07 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The anti-inflammatory and immunomodulating effects of dimethyl fumarate and its metabolite </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monomethyl fumarate are not fully elucidated but are thought to be mainly due to the interaction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the intracellular reduced glutathione of cells directly involved in the pathogenesis of psoriasis. This </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">interaction with glutathione leads to the inhibition of translocation into the nucleus and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">transcriptional activity of the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x3ba;B</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The main activity of dimethyl fumarate and monomethyl fumarate is considered to be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">immunomodulatory, resulting in a shift in T helper cells (Th) from the Th1 and Th17 profile to a Th2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">phenotype. The inflammatory cytokine production is reduced with induction of proapoptotic events, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibition of keratinocyte proliferation, reduced expression of adhesion molecules, and diminished </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inflammatory infiltrate within psoriatic plaques. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy and safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Skilarence was assessed in one double-blind, 3-arm, placebo- and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">comparator-controlled Phase III study (1102) in patients with moderate to severe plaque psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(Study 1102). 704 patients were randomised to receive Skilarence, an active comparator (Fumaderm, a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination product with the same content of dimethyl fumarate plus 3 monoethyl fumarate salts) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo in a ratio of 2:2:1. Patients began treatment with tablets containing 30 mg/day dimethyl </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fumarate or placebo, titrating up to a maximum of 720 mg/day in both active treatment arms as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">described in section 4.2. If treatment success was observed before the maximum dose of 720 mg/day </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of dimethyl fumarate was reached, no further increase of dose was necessary and the dose was to be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">steadily reduced to an individual maintenance dose. In case of individual intolerability of the increased </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose during weeks 4 to 16, the patient was to return to the last tolerated dose taken since the start of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">week 4, which was to be maintained until end of the treatment period (week 16). Patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment for up to 16 weeks and follow-up visits were planned for up to 12 months after treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was stopped. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The demographic and baseline characteristics were well balanced between the treatment groups. Of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the 699 patients, most were Caucasian (99%) and male (65%), and the mean age was 44 years. Most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients (91%) were </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&lt;65</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> years of age. Most patients had moderate psoriasis based on Psoriasis Area </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and Severity Index (PASI) and Physician&#x2019;s Global Assessment (PGA) scores at baseline: the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PASI score at baseline was 16.35 and 60% of patients scored as moderate on the PGA. The majority of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients reported a &#x201c;very large&#x201d; or &#x201c;extremely large&#x201d; effect of psoriasis on their life based on the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dermatology Life Quality Index (DLQI), with a mean DLQI score of 11.5. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After 16 weeks of treatment, Skilarence was found t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">o be superior to placebo (p&lt;0.000</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1) based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PASI 75 and PGA score clear or almost clear and non-inferior (using a non-inferiority margin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of -15%) to the active comparator </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p&lt;0.0003</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) based on PASI 75.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Summary of clinical efficacy after 16 weeks treatment in Study 1102 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Assessment </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:292pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Skilarence </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:380pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Placebo </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:454pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Fumaderm </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:301pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">N=267</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:382pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">N=131</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:464pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">N=273</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Superiority testing vs placebo </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">PASI 75</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">, n (%)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:294pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">100 (37.5)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">20 (15.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:457pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">110 (40.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt;0.0</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">001</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">a </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:418pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt;0.0001</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">a </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Two-sided 99.24% CI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:334pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">10.7, 33.7</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:411pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">13.5, 36.6</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">PGA score clear or almost clear,</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> n (%)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:297pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">88 (33.0)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:378pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">17 (13.0)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:457pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">102 (37.4)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt;0.0001</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:418pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">&lt;0.0001</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">Two-sided 99.24% CI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">9.0, 31.0</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:411pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">13.3, 35.5</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt"> a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:335pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Skilarence </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:443pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Fumaderm </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:343pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">N=267</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:453pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">N=273</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">Non-inferiority of Skilarence vs. Fumaderm </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:357pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:467pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">PASI 75</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">, n (%)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:337pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">100 (37.5) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:447pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">110 (40.3) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:399pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.0003</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">One-sided 97.5% repeated CI (lower limit) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-11.6</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt">PGA score clear or almost clear,</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> n (%)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:339pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">88 (33.0) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:447pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">102 (37.4)</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:9.96pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">p-value </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:399pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">0.0007</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:78pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">One-sided 97.5% repeated CI (lower limit) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:402pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt">-13.0</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.48pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9.96pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Fumaderm = Active comparator, a combination product with the same content of dimethyl fumarate plus 3 monoethyl </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">hydrogen fumarate sa</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">lts; n=number of patients with available data; N=number of patients in population; P</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">ASI=Psoriasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">Area Severity Index</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">; PGA=Physician&#x2019;s Global Assessment;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6pt">a</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> Superiority of Skilarence vs. Placebo with a difference of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">22.2% for PASI 75 and 20.0% for PGA score clear or almost clear, superiority of Fumaderm vs Placebo with a difference of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">25.0% for PASI 75 and 24.4% for PGA score clear or almos</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">t clear;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6pt">b</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt"> Non-inferiority of Skilarence vs. Fumaderm with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:738pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:9pt">difference of -2.8% for PASI 75 and -4.4% for PGA score clear or almost clear. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:749pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:762pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was a trend in the efficacy endpoint PASI score mean % change from baseline, indicating the </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">onset of a clinical response to Skilarence as early as week 3 (-11.8%) which became statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant compared to placebo by week 8 (-30.9%). Further improvement was seen by week 16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(-50.8%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The benefits of treatment with Skilarence were also supported by patient self-perceived improvements </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in their quality of life. At week 16, patients treated with Skilarence had a lower mean DLQI compared </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to placebo (5.4 vs 8.8).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Rebound </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(defined as worsening of &#x2265;125%</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of baseline PASI value) was assessed after 2 months off </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment and was shown not to be a clinical concern with fumaric acid esters, as it was documented in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very few patients (Skilarence 1.1% and active comparator 2.2%, compared to 9.3% in the placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Long-term efficacy data are currently not available for Skilarence, however, in the pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and clinical studies the systemic exposure, efficacy and safety of Skilarence were shown to be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">comparable to the active comparator containing dimethyl fumarate. Hence it is reasonable to expect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the long-term efficacy of Skilarence to also be comparable to dimethyl fumarate-containing products. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Maintenance of long term efficacy has been well described for other dimethyl fumarate-containing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products, and therefore the treatment benefits seen with Skilarence at 16 weeks can be expected to be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintained in patients treated over the long term for at least 24 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The European Medicines Agency has waived the obligation to submit the results of studies with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence in all subsets of the paediatric population in psoriasis (see section 4.2 for information on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">paediatric use). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After oral administration, dimethyl fumarate is not detected in plasma because it is rapidly hydrolysed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">by esterases to its active metabolite monomethyl fumarate. After oral administration of a single </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 120 mg tablet in healthy subjects, monomethyl fumarate reached plasma peak </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concentrations of around 1325 ng/mL and 1311 ng/mL under fasted or fed conditions, respectively. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Taking Skilarence with food delayed the t</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> of monomethyl fumarate from 3.5 to 9.0 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The plasma protein binding of monomethyl fumarate is around 50%. Dimethyl fumarate does not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">show any binding affinity to serum proteins which may further contribute to its rapid elimination from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the circulation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The biotransformation of dimethyl fumarate does not involve cytochrome P450 isoenzymes.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> In vitro </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies have shown that monomethyl fumarate at the therapeutic dose does not inhibit or induce any of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the cytochrome P450 enzymes, it is not a substrate or inhibitor of P-glycoprotein and is not an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitor of the most common efflux and uptake transporters</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#4aa423">. </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies have shown that dimethyl </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fumarate at a therapeutic dose does not inhibit CYP3A4/5 and BCRP and is a weak P-glycoprotein </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitor. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies have shown that hydrolysis of dimethyl fumarate to monomethyl fumarate occurs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rapidly at pH 8 (pH in the small intestine), but not at pH 1 (pH in the stomach). A part of the total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dimethyl fumarate is hydrolysed by esterases and the alkaline milieu of the small intestine, while the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">remainder enters the portal vein blood. Further studies have shown that dimethyl fumarate (and to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">lesser extent monomethyl fumarate) reacts partially with reduced glutathione forming a glutathione-</span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adduct. These adducts were detected in animal studies in the intestinal mucosa of rats and to a smaller </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent in portal vein blood. Unconjugated dimethyl fumarate, however, cannot be detected in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">plasma of animals or psoriatic patients following oral administration. By contrast, unconjugated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">monomethyl fumarate is detectable in plasma. Further metabolism occurs through oxidation via the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tricarboxylic acid cycle forming carbon dioxide and water. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exhalation of CO</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> resulting from the metabolism of monomethyl fumarate is the primary route of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">elimination;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> only small amounts of intact monomethyl fumarate are excreted through urine or faeces. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The portion of dimethyl fumarate that reacts with glutathione, forming a glutathione-adduct, is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolised further to its mercapturic acid, which is excreted in the urine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The apparent terminal elimination half-life of monomethyl fumarate is about 2 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Linearity/non-linearity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Despite the high inter-subject variability, the exposure measured as AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> was generally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose-proportional after single dose administration of 4 x 30 mg dimethyl fumarate tablets (total dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of 120 mg) and 2 x 120 mg dimethyl fumarate tablets (total dose of 240 mg). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No specific studies have been performed in patients with renal impairment. However, because renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">elimination plays a minor role in the total clearance from plasma, it is unlikely that renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may affect the pharmacokinetic characteristics of Skilarence (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No specific studies have been performed in patients with hepatic impairment. However, as dimethyl </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fumarate is metabolised by esterases and the alkaline milieu of the small intestine without the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">involvement of cytochrome P450, hepatic impairment is not expected to influence exposure (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-clinical data reveal no special hazard for humans based on conventional studies of safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacology and genotoxicity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Toxicology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The kidney was identified as a major target organ of toxicity in non-clinical studies. Renal findings in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dogs included minimal to moderate tubular hypertrophy, increased incidence and severity of tubular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vacuolation and minimal to slight tubular degeneration, which were considered toxicologically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relevant. The no-observed adverse-effect-level (NOAEL) after 3 months of treatment was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">30 mg/kg/day, which corresponds to 2.9-fold and 9.5-fold the human systemic exposure at the highest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose (720 mg/day), as AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values, respectively. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproduction toxicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No fertility or pre- and post-natal development studies have been conducted with Skilarence. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There were no effects on foetal body weights or malformations attributed to maternal administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dimethyl fumarate during the embryo-foetal development study in rats. However, there was an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased number of foetuses with the variations &#x201c;supernumerary liver lobe&#x201d; and &#x201c;abnormal iliac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alignment&#x201d; at maternally toxic doses. The NOAEL for maternal and embryo-foetal toxicity was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">40 mg/kg/day, corresponding to 0.2-fold and 2.0-fold the human systemic exposure at the highest </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose (720 mg/day), as AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values, respectively. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dimethyl fumarate has been shown to cross the placental membrane into foetal blood in rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Carcinogenicity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No carcinogenicity studies have been performed for Skilarence. Based on available data suggesting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that fumaric acid esters may activate cellular pathways related to the development of renal tumours, a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">potential tumorigenic activity of exogenously administered dimethyl fumarate on the kidneys cannot </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be excluded.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 30 mg and 120 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Core </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cellulose microcrystalline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Croscarmellose sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Colloidal anhydrous silica </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium stearate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 30 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Coating </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Methacrylic acid-ethyl acrylate copolymer (1:1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Talc </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Triethyl citrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Titanium dioxide (E171) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Simethicone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 120 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Coating </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Methacrylic acid-ethyl acrylate copolymer (1:1) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Talc </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Triethyl citrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Titanium dioxide (E171) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Simethicone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Indigo carmine (E132) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sodium hydroxide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life</span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">This medicinal product does not require any special storage conditions. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:842pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 30 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">42, 70 and 210 gastro-resistant tablets in PVC/PVDC-aluminium blister packs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skilarence 120 mg gastro-resistant tablets </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">40, 70, 90, 100, 120, 180, 200, 240, 300, 360 and 400 gastro-resistant tablets in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">PVC/PVDC-aluminium blister packs. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No special requirements for disposal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Almirall, S.A. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ronda General Mitre, 151 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">08022 Barcelona </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Spain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/002 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/004 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/005 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/006 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/007 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/008 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/009 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/010 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/011 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/012 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/013 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/17/1201/014 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 23 June 2017 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 21 February 2022 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu.</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>




























</body>
</html> 

